Form 4: Adaptive Biotechnologies COO Julie Rubinstein Reports Stock Transactions
SEC Form 4 Filing
Julie Rubinstein, President and COO of Adaptive Biotechnologies, reports acquisition and disposal of company stock to cover tax obligations related to RSU vesting.
Summary
- On March 4, 2025, Julie Rubinstein, President and COO of Adaptive Biotechnologies, acquired 175,000 shares of common stock at $0.
- On March 5, 2025, she disposed of 40,044 shares at $6.98 and 19,461 shares at $6.99.
- These sales were to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
- Following these transactions, Rubinstein beneficially owns 588,249 shares of Adaptive Biotechnologies common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company officer. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Form 4 filings are a routine part of the equity markets, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Acquisition of 175,000 shares of common stock |
| 03/05/2025 | Sale of 40,044 shares at $6.98 and 19,461 shares at $6.99 |
| 03/06/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.